KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Operating Margin: 2009-2025

Historic Operating Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to 27.35%.

  • Regeneron Pharmaceuticals' Operating Margin fell 435.00% to 27.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.89%, marking a year-over-year decrease of 281.00%. This contributed to the annual value of 28.10% for FY2024, which is 275.00% down from last year.
  • Regeneron Pharmaceuticals' Operating Margin amounted to 27.35% in Q3 2025, which was down 6.88% from 29.37% recorded in Q2 2025.
  • Regeneron Pharmaceuticals' Operating Margin's 5-year high stood at 2,517.00% during Q1 2022, with a 5-year trough of 19.54% in Q1 2025.
  • Its 3-year average for Operating Margin is 28.33%, with a median of 29.37% in 2025.
  • Its Operating Margin has fluctuated over the past 5 years, first spiked by 247,300bps in 2022, then plummeted by 248,706bps in 2023.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Operating Margin stood at 53.31% in 2021, then skyrocketed by 109,349bps to 1,146.80% in 2022, then plummeted by 111,847bps to 28.33% in 2023, then tumbled by 220bps to 26.13% in 2024, then plummeted by 435bps to 27.35% in 2025.
  • Its Operating Margin was 27.35% in Q3 2025, compared to 29.37% in Q2 2025 and 19.54% in Q1 2025.